

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

AVENTIS PHARMACEUTICALS INC. and  
SANOFI-AVENTIS US LLC,

Plaintiffs,

v.

BARR LABORATORIES, INC.

Defendant.

C.A. No. 06-286 (GMS)


**NOTICE OF SUBPOENA**

PLEASE TAKE NOTICE that defendant Barr Laboratories, Inc. has served the attached subpoena upon Synnestvedt and Lechner.

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

OF COUNSEL:

George C. Lombardi  
Maureen L. Rurka  
WINSTON & STRAWN LLP  
35 West Wacker Drive  
Chicago, Illinois 60601  
(312) 558-5600

  
\_\_\_\_\_  
Josy W. Ingersoll (#1088)  
Karen L. Pascale (#2903)  
Karen E. Keller (#4489)  
The Brandywine Building  
1000 West Street, 17th Floor  
Wilmington, Delaware 19801  
(302) 571-6600  
jingersoll@ycst.com

*Attorneys for Defendant Barr Laboratories, Inc.*

Dated: November 7, 2006

~~SAO88 (Rev. 1/94) Subpoena in a Civil Case~~

Issued by the  
UNITED STATES DISTRICT COURT

Eastern

DISTRICT OF

Pennsylvania

AVENTIS PHARMACEUTICALS, INC.  
AND SANOFI-AVENTIS US LLC  
V.

SUBPOENA IN A CIVIL CASE

BARR LABORATORIES, INC

Case Number:<sup>1</sup> C.A. No. 06-286 (GMS)  
(For a case pending in the District of  
Delaware)

TO: SYNNESTVEDT AND LECHNER,  
2600 ARAMARK TOWER  
1101 Market Street  
Philadelphia, PA 19107-2950

- ☐ YOU ARE COMMANDED to appear in the United States District court at the place, date, and time specified below to testify in the above case.

PLACE OF TESTIMONY	COURTROOM
	DATE AND TIME

- ☐ YOU ARE COMMANDED to appear at the place, date, and time specified below to testify at the taking of a deposition in the above case.

PLACE OF DEPOSITION	DATE AND TIME
---------------------	---------------

- ☒ YOU ARE COMMANDED to produce and permit inspection and copying of the following documents or objects at the place, date, and time specified below (list documents or objects):

See Exhibit A attached.

PLACE	SYNNESTVEDT AND LECHNER, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA 19107-2950	DATE AND TIME	November 20, 2006
<input type="checkbox"/> YOU ARE COMMANDED to permit inspection of the following premises at the date and time specified below.			
PREMISES	DATE AND TIME		

Any organization not a party to this suit that is subpoenaed for the taking of a deposition shall designate one or more officers, directors, or managing agents, or other persons who consent to testify on its behalf, and may set forth, for each person designated, the matters on which the person will testify. Federal Rules of Civil Procedure, 30(b)(6).

ISSUING OFFICER'S SIGNATURE AND TITLE (INDICATE IF ATTORNEY FOR PLAINTIFF OR DEFENDANT)	DATE
Eric Broxterman, Attorney for Barr Laboratories, Inc.	October 20, 2006
ISSUING OFFICER'S NAME, ADDRESS AND PHONE NUMBER	
Eric Broxterman, Winston & Strawn LLP, 35 West Wacker Dr., Chicago, IL 60601 (312) 558-5600	

(See Rule 45, Federal Rules of Civil Procedure, Parts C & D on next page)

<sup>1</sup> If action is pending in district other than district of issuance, state district under case number.

AO88 (Rev. 1/94) Subpoena in a Civil Case

## PROOF OF SERVICE

DATE

PLACE

SERVED

SERVED ON (PRINT NAME)

MANNER OF SERVICE

SERVED BY (PRINT NAME)

TITLE

## DECLARATION OF SERVER

I declare under penalty of perjury under the laws of the United States of America that the foregoing information contained in the Proof of Service is true and correct.

Executed on

DATE

SIGNATURE OF SERVER

ADDRESS OF SERVER

## Rule 45, Federal Rules of Civil Procedure, Parts C &amp; D:

## (c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.

(1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction which may include, but is not limited to, lost earnings and reasonable attorney's fee.

(2) (A) A person commanded to produce and permit inspection and copying of designated books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.

(B) Subject to paragraph (d) (2) of this rule, a person commanded to produce and permit inspection and copying may, within 14 days after service of subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to inspection or copying of any or all of the designated materials or of the premises. If objection is made, the party serving the subpoena shall not be entitled to inspect and copy materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production. Such an order to compel production shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection and copying commanded.

(3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it

(i) fails to allow reasonable time for compliance,

(ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that, subject to the provisions of clause (c) (3) (B) (iii) of this rule, such a person may in order to attend

trial be commanded to travel from any such place within the state in which the trial is held, or

(iii) requires disclosure of privileged or other protected matter and no exception or waiver applies, or

(iv) subjects a person to undue burden.

## (B) If a subpoena

(i) requires disclosure of a trade secret or other confidential research, development, or commercial information, or

(ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or

(iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject to or affected by the subpoena, quash or modify the subpoena, or, if the party in whose behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

## (d) DUTIES IN RESPONDING TO SUBPOENA.

(1) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.

(2) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.

**Exhibit A**

**DOCUMENT REQUESTS**

**DEFINITIONS**

1. “Synnestvedt & Lechner LLP” shall mean the law firm listed in the file history for the ‘329 and ‘573 patents and shall include all attorneys, employees, agents, representatives, or persons acting on behalf of Synnestvedt & Lechner LLP.

2. “Barr” shall mean Barr Laboratories, Inc. and all its affiliates and subsidiaries.

3. “Aventis” shall mean Aventis Pharmaceuticals Inc., a named plaintiff to the Current Litigation, and a corporation organized and existing under the laws of the State of Delaware, and any of its present or former divisions, and shall also include any present or former parent, subsidiary, affiliated or related corporation or any other related entity of Aventis Pharmaceuticals Inc. “Aventis” shall further mean all past or present directors, officers, employees, agents, representatives, or persons acting on behalf of any of the foregoing entities (including without limitation Rorer Pharmaceutical Products, Inc. and Rhone-Poulec Rorer, Inc.).

4. “Sanofi-Aventis” shall mean Sanofi-Aventis US LLC, a named plaintiff to the Current Litigation, and a corporation organized and existing under the laws of the State of Delaware, and any of its present or former divisions, and shall also include any present or former parent, subsidiary, affiliated or related corporation or any other related entity of Sanofi-Aventis US LLC. “Sanofi-Aventis” shall further mean all past or present directors, officers, employees, agents, representatives, or persons acting on behalf of any of the foregoing entities.

5. “ANDA” shall mean an abbreviated new drug application as provided under 21 U.S.C. § 355(j), and the corresponding implementing regulations at 21 C.F.R. § 314 *et seq.*

6. “NDA” shall mean New Drug Application No. 20-468 filed with the FDA and held by Sanofi-Aventis.

7. The “‘573 patent” shall mean U.S. Patent No. 5,976,573 issued on November 2, 1999.

8. The “‘329 patent” shall mean U.S. Patent No. 6,143,329 issued on November 7, 2000.

9. The term “patents-in-suit” shall mean U.S. Patent No. 5,976,573 and U.S. Patent No. 6,143,329 collectively.

10. The term “TAA” shall mean triamcinolone acetonide.

11. “Current Litigation” shall mean the lawsuit entitled *Aventis Pharmaceuticals Inc. and Sanofi-Aventis US LLC v. Barr Laboratories, Inc.*, Civil Action No. 06-286 (GMS), pending in the United States District Court for the District of Delaware.

12. “Related Litigation” shall mean any lawsuit filed by Aventis and/or Sanofi-Aventis wherein Aventis and/or Sanofi-Aventis has asserted either the ‘573 patent and/or the ‘329 patent.

13. “PTO” shall mean the U.S. Patent and Trademark Office.

14. “FDA” shall mean the U.S. Food and Drug Administration.

15. The terms “you” and “your” shall mean “Synnestvedt & Lechner LLP” as defined above.

16. The term “communication” means the transmittal of information (in the form of facts, ideas, inquiries or otherwise).

17. The term “document” or “documents” is used herein in a comprehensive sense as set forth in Rule 34(a) of the Federal Rules of Civil Procedure, and shall be defined to include, without limitation, all tangible things, all written, printed, typed, photocopies, photographic, graphic or recorded matter of any kind, any recorded material however produced or reproduced, including agreements, books, calendars, charts, contracts, communications, computer databases, computer memory media, computer printouts, correspondence, desk pads, diaries, drafts, drawings, entries in books of account, electronic mail, facsimile transmissions, files, folders, graphs, guidelines, instructions, lists, manuals, memoranda, minutes, notes, operating procedures, pamphlets, reports, rules, studies, telegrams, teletypes, and all written or tangible things that can be derived from any computer database, microfilm, microfiche, or other storage medium. A draft or non-identical copy is a separate document within the meaning of this term.

18. The term “person” is defined as any natural person or any business, legal or governmental entity or association.

19. When referring to a person, “identify” means to give, to the extent known, the person’s full name, present or last known address, and when referring to a natural person, additionally, the present or last known place of employment.

20. When referring to documents, “identify” means to give, to the extent known, the: (i) type of document; (ii) general subject matter; (iii) date of the document; and (iv) author(s), addressee(s), and recipient(s).

21. The term “concerning” means relating to, referring to, describing, evidencing, or constituting.

22. Something is “relating to” a subject if it makes a statement about, refers to, mentions, discusses, describes, reflects, deals with, consists of, constitutes, comprises, concerns, evidences, records, or in any way pertains to the subject, either in whole or in part, and either directly or indirectly.

23. The terms “all” and “each” shall be construed as all and each.

24. The connectives “and” and “or” shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the discovery request all responses that might otherwise be construed to be outside its scope.

25. The use of the singular form of any word includes the plural and vice versa.

26. The term “including” means without limitation.

#### **INSTRUCTIONS**

1. No request shall be construed with reference to any other request for purposes of limitation.

2. Each requested document shall be produced in its entirety, including all attachments and enclosures. If a portion of a document is responsive to a request, produce the entire document, including all attachments, enclosures, "post-it"-type notes, and any other matter physically attached to the document. If a document responsive to any request cannot be produced in full, it shall be produced to the extent possible with an explanation stating why production of the remainder is not possible.

3. If a document responsive to any request is no longer in your possession, custody, or control, state: (i) its date; (ii) author(s); (iii) recipient(s); (iv) subject matter; (v) when such document was most recently in your possession, custody, or control; (vi) what disposition was made of the document; and, (vii) the person or entity, if any, now in possession, custody, or control of the document. If a document has been destroyed, identify: (i) the date of destruction; (ii) the person who destroyed the document(s); (iii) the person who directed the document to be destroyed; and, (iv) the reason(s) for its destruction.

4. All documents produced in response to these requests shall be produced in the same order as they are kept in the ordinary course of business and, where attached, shall not be separated or disassembled. If documents responsive to any request are normally kept in a file or folder, also produce that file or folder with any labels attached thereto, and indicate the company, division, department, and/or individual from whose files the document is being produced. If responsive documents are segregated or separated from other documents, whether by inclusion in binders, files, sub-files, or by use of dividers, tabs or any other method, produce such documents in that form.



5. If, in responding to these document requests, you claim any ambiguity in interpreting either a request or a definition or instruction applicable thereto, such claim shall not be utilized by you as a basis for refusing to respond, but you shall set forth as part of your response to the request the language deemed to be ambiguous and the interpretation chosen to be used in responding to the request.

6. If, in responding to these document requests, you assert a privilege to any particular request, you must identify the nature of the privilege (including work product) that is being claimed, and, if the privilege is governed by state law, indicate the state's privilege rule being invoked. In addition, the following information shall be provided in the objection:

- a. For documents: (i) the type of document; (ii) the general subject matter of the document; (iii) the date of the document; and (iv) such other information as is sufficient to identify the document for a subpoena duces tecum, including, where appropriate, the author of the document, the addressees of the document, and all recipients of the document, and, where not apparent, the capacities of the author, addressees, and recipients and their relationship to each other;
- b. For oral communications: (i) the name of the person making the communication and the names of persons present while the communication was made and, where not apparent, the capacities of the author and the relationship of the persons present to the person making the communication; (ii) the date and place of communication; and (iii) the general subject matter of the communication.

7. Each request for documents is continuing in nature. If, after responding to these requests, you obtain or become aware of further documents responsive to any request, such documents shall be produced promptly in accordance with Rule 26(e) of the Federal Rules of Civil Procedure and the definitions and instructions herein.

**DOCUMENTS REQUESTED**

1. All documents concerning, relating, or referring to the '573 patent, including but not limited to:

- a. all documents surrounding the alleged invention of the '573 patent, including but not limited to, all documents and/or things that were considered in connection with the development of the invention allegedly disclosed in the '573 patent, and/or in connection with the prosecution of the patent, regardless of whether such documents or information was cited to the PTO;
- b. all laboratory notebooks or other documents relating to or concerning the conception and/or reduction to practice of the alleged invention of the '573 patent, including but not limited to, (i) documents concerning the identity of the individuals who allegedly conceived of, and/or reduced to practice or assisted in the reduction to practice of, the invention claimed, and (ii) documents concerning the date(s) on which such alleged conception and/or reduction to practice occurred;
- c. all inventor disclosure statements;
- d. all documents concerning the subject matter of the '573 patent;
- e. all documents concerning or relating to any contract, agreement, grant, sponsorship or compensation paid or received in connection with any tests, studies, analyses, investigations, reports, comparisons or opinions conducted, prepared, or performed concerning or relating to the subject matter described and/or claimed in the '573 patent and the prosecution of the '573 patent; and
- f. all documents concerning or relating to any tests, studies, analyses, investigations, reports, comparisons, or opinions concerning or relating to the '573 patent, including but not limited to any contract, agreement, grant, sponsorship or compensation paid or received in connection with any such tests, studies, analyses, investigations, reports, comparisons or opinions.

2. All documents concerning, relating, or referring to the '329 patent, including but not limited to:

- a. all documents surrounding the alleged invention of the '329 patent, including but not limited to, all documents and/or things that were considered in connection with the development of the invention allegedly disclosed in the '329 patent, and/or in connection with the prosecution of the patent, regardless of whether such documents or information was cited to the PTO;

- b. all laboratory notebooks or other documents relating to or concerning the conception and/or reduction to practice of the alleged invention of the '329 patent, including but not limited to, (i) documents concerning the identity of the individuals who allegedly conceived of, and/or reduced to practice or assisted in the reduction to practice of, the invention claimed, and (ii) documents concerning the date(s) on which such alleged conception and/or reduction to practice occurred;
  - c. all inventor disclosure statements;
  - d. all documents concerning the subject matter of the '329 patent;
  - e. all documents concerning or relating to any contract, agreement, grant, sponsorship or compensation paid or received in connection with any tests, studies, analyses, investigations, reports, comparisons or opinions conducted, prepared, or performed concerning or relating to the subject matter described and/or claimed in the '329 patent and the prosecution of the '329 patent; and
  - f. all documents concerning or relating to any tests, studies, analyses, investigations, reports, comparisons, or opinions concerning or relating to the '329 patent, including but not limited to any contract, agreement, grant, sponsorship or compensation paid or received in connection with any such tests, studies, analyses, investigations, reports, comparisons or opinions.
3. All documents concerning or relating to the prosecution of the '573 patent, including but not limited to:
- a. all documents relating to the filing and prosecution of the '573 patent, including but not limited to, (i) the preparation and drafting of Application No. 08/678,465; (ii) any and all literature reports, prior art, or other documents, regardless of whether such information was cited to the PTO, reviewed, considered, analyzed or otherwise referenced in considering to prosecute or in prosecuting the '573 patent; (iii) all documents identifying all pieces of prior art located, but not submitted to the PTO in connection with the prosecution of the '573 patent; and (iv) testing results or any other documents supporting the prosecution and/or claims of the '573 patent;
  - b. all documents submitted or otherwise received from the PTO in connection with the filing and prosecution of the '573 patent;
  - c. all documents supporting any statement made in any response to an office action, submitted on Soo Il-Kim's behalf during the prosecution of the '573 patent;
  - d. all documents relating to any telephone conference with the PTO during the prosecution of the '573 patent;

- e. all documents concerning any rejection by the PTO of the claims of the '573 patent; and
  - f. all prior art or potential prior art collected, considered or otherwise reviewed with respect to the '573 patent, whether or not submitted to the PTO.
4. All documents concerning or relating to the prosecution of the '329 patent, including but not limited to:

- a. all documents relating to the filing and prosecution of the '329 patent, including but not limited to, (i) the preparation and drafting of Application No. 09/315,454; (ii) any and all literature reports, prior art, or other documents, regardless of whether such information was cited to the PTO, reviewed, considered, analyzed or otherwise referenced in considering to prosecute or in prosecuting the '329 patent; (iii) all documents identifying all pieces of prior art located, but not submitted to the PTO in connection with the prosecution of the '329 patent; and (iv) testing results or any other documents supporting the prosecution and/or claims of the '329 patent.
  - b. all documents submitted or otherwise received from the PTO in connection with the filing and prosecution of the '329 patent;
  - c. all documents supporting any statement made in any response to an office action, submitted on Soo Il-Kim's behalf during the prosecution of the '329 patent;
  - d. all documents relating to any preliminary amendment during the prosecution of the '329 patent
  - e. all documents relating to any telephone conference with the PTO during the prosecution of the '329 patent;
  - f. all documents concerning any rejection by the PTO of the claims of the '329 patent; and
  - g. all prior art or potential prior art collected, considered or otherwise reviewed with respect to the '329 patent, whether or not submitted to the PTO.
5. All documents and things concerning, relating, or referring to any license, offer to license or other agreement, assignment, transfer or lien, or contingent or future interest in the

'573 patent, including any payments, compensation or royalties paid to or otherwise received by Soo-Il Kim or on his behalf.

6. All documents and things concerning, relating, or referring to any license, offer to license or other agreement, assignment, transfer or lien, or contingent or future interest in the '329 patent, including any payments, compensation or royalties paid to or otherwise received by Soo-Il Kim or on his behalf.

7. All documents and things concerning, relating, or referring to either of the two patients and/or volunteers that were identified in the patents-in-suit that were obtained, reviewed, researched or otherwise investigated in connection with the patents-in-suit, your representation of Soo-Il Kim, and/or the prosecution of the patents-in-suit, including but not limited to:

- a. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or under his direction, with either of the patients/volunteers, including but not limited to, testing on patients with allergic rhinitis;
- b. documents concerning or relating to any use of or treatment of either the patients/volunteers (whether actual or proposed);
- c. documents concerning or relating to any clinical study involving either of the patients/volunteers, including but not limited to, protocols and/or directions of the clinical studies; and
- d. any reports, publications, articles or patents concerning, referring to or relating to either of the patients/volunteers, including, but not limited to, such documents for which Soo-Il Kim is an author or co-author.

8. All documents and things concerning, relating, or referring to the studies, authors, doctors, patients and/or volunteers that were identified in the paper by Guy Settipane, MD, et al., entitled "Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with

Seasonal Ragweed Allergic Rhinitis: A Placebo-Controlled, Double Blind Study” that were obtained, reviewed, researched or otherwise investigated in connection with the patents-in-suit, your representation of Soo-Il Kim, and/or the prosecution of the patents-in-suit.

9. All documents and things concerning, relating, or referring to the studies, authors, doctors, patients and/or volunteers that were identified in the paper by Roger H. Kobayashi, MD, et al., entitled “Triamcinolone Acetonide Aqueous Nasal Spray for the Treatment of Patients with Perennial Allergic Rhinitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study” that were obtained, reviewed, researched or otherwise investigated in connection with the patents-in-suit, your representation of Soo-Il Kim, and/or the prosecution of the patents-in-suit.

10. All documents and things concerning, relating, or referring to allergic rhinitis that were obtained, reviewed, researched or otherwise investigated in connection with the patents-in-suit, your representation of Soo-Il Kim, and/or the prosecution of the patents-in-suit, including but not limited to:

- a. any testing performed on persons with allergic rhinitis;
- b. any reports, publications, articles or patents concerning, referring to or relating to allergic rhinitis, including but not limited to, such documents for which Soo-Il Kim, Guy Settipane, or Roger Kobayshi is an author or co-author; and
- c. all documents and things concerning, referring to or relating to the market for drugs used for the treatment of allergic rhinitis.

11. Any and all communications with, between or among you, Soo-Il Kim, Aventis, Sanofi-Aventis and/or any other person or entity relating, concerning, or relating to:

- a. the ‘573 patent;
- b. the ‘329 patent;

- c. the Current Litigation;
- d. any Related Litigation;
- e. the alleged invention of the '573 patent;
- f. the alleged invention of the '329 patent;
- g. Application No. 08/678,465, including the filing of that application;
- h. Application No. 09/315,454, including the filing of that application;
- i. the prosecution of the '573 patent;
- j. the prosecution of the '329 patent
- k. any ANDA referencing NDA No. 20-468;
- l. any notification received under 21 U.S.C. § 355(j) referencing NDA No. 20-468;
- m. either of the patients and/or volunteers mentioned in the patents-in-suit;
- n. clinical studies relating to allergic rhinitis;
- o. the deposition of medicaments in the nasal cavity;
- p. the amount of time medicaments are retained in the mucosal surfaces; and
- q. allergic rhinitis.

12. All documents concerning NDA No.20-468, including but not limited to studies, papers or documents cited in the NDA.

13. All documents and things concerning, relating, or referring to the composition of the invention of the patents-in-suit that were obtained, reviewed, researched or otherwise investigated in connection with your representation of Soo-Il Kim and the prosecution of the patents-in-suit, including but not limited to:

- a. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or at your direction, relating to thixotropic properties of glucocorticosteroids;

- b. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or at your direction, relating to nasal deposition pattern testing;
- c. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or at your direction, relating to the viscosity of glucocorticosteroids;
- d. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or at your direction, relating to the deposition of medicaments in the nasal cavity; and
- e. any testing or experiments conducted or funded by Soo-Il Kim or on his behalf, either directly or indirectly, or at your direction, relating to the amount of time medicaments were retained on the mucosal surfaces.

14. All documents relating to the disposal or destruction of any documents that would have been responsive to Defendants' subpoena but are no longer in your possession, custody or control.



**CERTIFICATE OF SERVICE**

I, Josy W. Ingersoll, Esquire, hereby certify that on November 7, 2006, I caused to be electronically filed a true and correct copy of the foregoing document with the Clerk of the Court using CM/ECF, which will send notification that such filing is available for viewing and downloading to the following counsel of record:


Steven J. Balick, Esquire  
John G. Day, Esquire  
Tiffany Geyer Lydon, Esquire  
ASHBY & GEDDES  
222 Delaware Avenue, 17th Floor  
Wilmington, DE 19801

I further certify that on November 7, 2006, I caused a copy of the foregoing document to be served by hand delivery on the above-listed counsel of record and on the following non-registered participants in the manner indicated:

**BY E-MAIL**

Paul H. Berghoff, Esquire	berghoff@mbhb.com
Joshua R. Rich, Esquire	rich@mbhb.com
Jeremy E. Noe, Esquire	noe@mbhb.com
Paul S. Tully, PhD.	tully@mbhb.com
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 South Wacker Drive Chicago, Illinois 60606	

YOUNG CONAWAY STARGATT &  
TAYLOR, LLP

  
\_\_\_\_\_  
Josy W. Ingersoll (#1088)  
Karen L. Pascale (#2903)  
Karen E. Keller (#4489)  
The Brandywine Building  
1000 West Street, 17th Floor  
Wilmington, Delaware 19801  
(302) 571-6600  
jingersoll@ycst.com